Citations

Clear

572 citation(s) found for "Silva, P".

Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas
Qin, Yuejuan, Cheng, Zi-Ming, Gao, Qing , Silva, Gustavo M. , Prasad, Manju L. , Ocal, Idris Tolgay, Rao, Sarika , Aronin, Neil , Barontini, Marta, Bruder, Jan , Reddick, Robert L., Aguiar, Ricardo C.T. , Ocal, I Tolgay, Toledo, Rodrigo A , Iwata, Shintaro , Chen, Yidong , Dahia, Patricia L. M. , Rao, Sarika N

Mayo Clinic

Clinical Cancer Research | December 23, 2015 | Volume: 22 | Issue: 9 | Pages: 2301-2310

10.1158/1078-0432.ccr-15-1841 | PMID 26700204 Get It

Abstract Purpose: Pheochromocytomas and paragangliomas (PPGL) are genetically heterogeneous tumors of neural crest origin, but the molecular basis of most PPGLs is unknown. Experimental Design: We performed exome or transcriptome sequencing of 43 samples from 41 patients. A validation set of 136 PPGLs was used for amplicon-specific resequencing. In addition, a subset of these tumors was subjected to microarray-based transcription, protein expression, and histone methylation analysis by Western blotting or immunohistochemistry. In vitro analysis of mutants was performed in cell lines. Results: We detected mutations in chromatin-remodeling genes, including histone-methyltransferases, histone-demethylases, and histones in 11 samples from 8 patients (20%). In particular, we characterized a new cancer syndrome involving PPGLs and giant cell tumors of bone (GCT) caused by a postzygotic G34W mutation of the histone 3.3 gene, H3F3A. Furthermore, mutations in kinase genes were detected in samples from 15 patients (37%). Among those, a novel germline kinase domain mutation of MERTK detected in a patient with PPGL and medullary thyroid carcinoma was found to activate signaling downstream of this receptor. Recurrent germline and somatic mutations were also detected in MET, including a familial case and sporadic PPGLs. Importantly, in each of these three genes, mutations were also detected in the validation group. In addition, a somatic oncogenic hotspot FGFR1 mutation was found in a sporadic tumor. Conclusions: This study implicates chromatin-remodeling and kinase variants as frequent genetic events in PPGLs, many of which have no other known germline driver mutation. MERTK, MET, and H3F3A emerge as novel PPGL susceptibility genes. Clin Cancer Res; 22(9); 2301–10. ©2015 AACR.
Walker 256 tumor‐bearing rats demonstrate altered interstitial cells of Cajal. Effects on ICC in the Walker 256 tumor model
Fracaro, Luciane , Frez, Flávia Cristina Vieira , Silva, B. C., Vicentini, Geraldo Emı́lio , Souza, Sara Raquel Garcia de , Martins, Heber Amilcar , Guarnier, Flávia Alessandra , Zanoni, Jacqueline Nelisis , Linden, David R.

Mayo Clinic

Neurogastroenterology & Motility | November 3, 2015 | Volume: 28 | Issue: 1 | Pages: 101-115

10.1111/nmo.12702 | PMID 26526599 Get It

AbstractBackgroundCachexia is a significant problem in patients with cancer. The effect of cancer on interstitial cells of Cajal (ICC) and neurons of the gastrointestinal tract have not been studied previously. Although supplementation with L‐glutamine 2% may have beneficial effects in cancer‐related cachexia, and be protective of ICC in models of oxidative stress such as diabetes, its effects on ICC in cancer have also not been studied.MethodsTwenty‐eight male Wistar rats were divided into four groups: control (C), control supplemented with L‐glutamine (CG), Walker 256 tumor (WT), and Walker 256 tumor supplemented with L‐glutamine (WTG). Rats were implanted with tumor cells or injected with saline in the right flank. After 14 days, the jejunal tissues were collected and processed for immunohistochemical techniques including whole mounts and cryosections and Western blot analysis.Key ResultsTumor‐bearing rats demonstrate reduced numbers of Myenteric ICC and deep muscular plexus ICC and yet increased Ano1 protein expression and enhanced ICC networks. In addition, there is more nNOS protein expressed in tumor‐bearing rats compared to controls. L‐glutamine treatment had a variety of effects on ICC that may be related to the disease state and the interaction of ICC and nNOS neurons. Regardless, L‐glutamine reduced the size of tumors and also tumor‐induced cachexia that was not due to altered food intake.Conclusions & InferencesThere are significant effects on ICC in the Walker 256 tumor model. Although supplementation with L‐glutamine has differential and complex effects of ICC, it reduces tumor size and tumor‐associated cachexia, which supports its beneficial therapeutic role in cancer.
Classification of current anticancer immunotherapies
Galluzzi, Lorenzo , Vacchelli, Erika , Pedro, José Manuel Bravo‐San , Buqué, Aitziber , Senovilla, Laura , Baracco, Elisa Elena, Bloy, Norma , Castoldi, Francesca , Abastado, Jean-Pierre, Agostinis, Patrizia , Apte, Ron N., Aranda, Fernando , Ayyoub, Maha , Beckhove, Philipp , Blay, Jean‐Yves , Bracci, Laura , Caignard, Anne , Cavallo, Federica , Celis, Estaban, Clayton, Aled , Coussens, Lisa M. , Dhodapkar, Madhav V. , Eggermont, Alexander , Fearon, Douglas T. , Fučíková, Jitka , Galon, Jérôme , Garg, Abhishek D. , Ghiringhelli, François , Gilboa, Eli , Gnjatic, Sacha , Hoos, Axel , Jäger, Dirk, Kaliński, Paweł , Kärre, Klas , Kepp, Oliver , Kiessling, Rolf , Klein, Eva, Knuth, Alexander, Lewis, Claire E. , Lugli, Enrico , Mach, J P, Mattei, Fabrizio , Mavilio, Domenico , Melero, Ignacio , Melief, Cornelis J.M., Moretta, Lorenzo , Odunsi, Adekunke, Palucka, A. Karolina, Porgador, Angel , Prendergast, George C. , Restifo, Nicholas P. , Rizvi, Naiyer A. , Schreiber, Hans , Seliger, Barbara , Shiku, Hiroshi , Špíšek, Radek , Srivastava, Pramod K. , Vile, Richard G. , Wagner, Hermann, Weber, Jeffrey S. , Zitvogel, Laurence , Zou, Weiping , Abastado, Jean‐Pierre, Castelli, Chiara , Cerundolo, Vincenzo , Colombo, Mario P. , Fridman, Wolf H. , Gabrilovich, Dmitry I. , Giaccone, Giuseppe , Hosmalin, Anne , Kirkwood, John M. , Liblau, Roland , Lotze, Michael T. , Mittendorf, EA , Okada, Hideho , Peter, Marcus E. , Pienta, Kenneth J , Rabinovich, Gabriel A , Sautès‐Fridman, Catherine , Silva‐Santos, Bruno , Smyth, Mark J. , Speiser, Daniel E. , Talmadge, James E. , Tartour, Éric , Burg, Sjoerd H. van der , Eynde, Benoı̂t J. Van den , Whiteside, Theresa L , Wolchok, Jedd D. , Kroemer, Guido , Gnjatic, Sacha , Blay, Jean-Yves , Galon, Jerome , Weber, Jeffrey

Mayo Clinic

Oncotarget | September 15, 2015 | Volume: 5 | Issue: 24 | Pages: 12472-12508

10.18632/oncotarget.2998 | PMID 25537519 Get It

2015 Recommendations for the Management of Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative
Dejaco, Christian , Singh, Yogesh Preet , Perel, Pablo , Hutchings, Andrew , Camellino, Dario , Mackie, Sarah , Abril, Andy , Bachta, Artur , Bálint, Péter, Barraclough, Kevin, Bianconi, L., Buttgereit, Frank , Carsons, Steven E. , Ching, Daniel , Cid, María C. , Cimmino, Marco A. , Diamantopoulos, Andreas P. , Docken, William P., Duftner, Christina , Fashanu, Billy, Gilbert, Kate, Hildreth, Pamela, Hollywood, Jane, Jayne, David , Lima, Manuella , Maharaj, Ajesh B. , Mallen, Christian , Martínez‐Taboada, Víctor M. , Maz, Mehrdad , Merry, Steven, Miller, Jean , Mori, Shunsuke , Nordborg, Elisabeth, Nott, Jennifer, Padbury, Hannah, Pease, Colin, Salvarani, Carlo , Schirmer, Michael , Schmidt, Wolfgang , Tronnier, David, Wagner, Alexandre, Whitlock, Madeline, Matteson, Eric L. , Merry, Stephen , Souza, Alexandre Wagner Silva de , Neill, Lorna M. , Salvarani, Carlo , Spiera, Robert , Wagner, Alexandre, Dasgupta, Bhaskar , Dejaco, Christian , Merry, Stephen P , Mackie, Sarah Louise , Jayne, David , Buttgereit, Frank , Singh, Yogesh Preet , de Souza, Alexandre Wagner Silva

Mayo Clinic

Arthritis & Rheumatology | September 10, 2015 | Volume: 67 | Issue: 10 | Pages: 2569-2580

10.1002/art.39333 | PMID 26352874 Get It

Abstract Therapy for polymyalgia rheumatica (PMR) varies widely in clinical practice as international recommendations for PMR treatment are not currently available. In this paper, we report the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of PMR. We used the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology as a framework for the project. Accordingly, the direction and strength of the recommendations are based on the quality of evidence, the balance between desirable and undesirable effects, patients’ and clinicians’ values and preferences, and resource use. Eight overarching principles and nine specific recommendations were developed covering several aspects of PMR, including basic and follow‐up investigations of patients under treatment, risk factor assessment, medical access for patients and specialist referral, treatment strategies such as initial glucocorticoid (GC) doses and subsequent tapering regimens, use of intramuscular GCs and disease modifying anti‐rheumatic drugs (DMARDs), as well as the roles of non‐steroidal anti‐rheumatic drugs and non‐pharmacological interventions. These recommendations will inform primary, secondary and tertiary care physicians about an international consensus on the management of PMR. These recommendations should serve to inform clinicians about best practices in the care of patients with PMR.
Non‐enteric infections, antibiotic use, and risk of development of functional gastrointestinal disorders
Grover, Madhusudan , Halder, Smita , Locke, G. Richard, Schleck, Cathy D. , Zinsmeister, Alan R., Paula, Hellen da Silva Cintra de , Talley, Nicholas J.

Mayo Clinic

Neurogastroenterology & Motility | August 25, 2015 | Volume: 27 | Issue: 11 | Pages: 1580-1586

10.1111/nmo.12655 | PMID 26303310 Get It

Abstract Background Gastrointestinal infections are risk factors for irritable bowel syndrome ( IBS ) and functional dyspepsia ( FD ). We investigated whether non‐enteric infections and antibiotic exposure are also associated with the development of functional gastrointestinal disorders ( FGID s). Methods In a nested case–control study, random samples of Olmsted County, MN , were mailed valid self‐report questionnaires from 1988 through 1994, and then follow‐up questionnaires from 1995 through 2003. Survey responders who did not report any FGID symptoms at baseline, but then reported such symptoms in at least one subsequent survey, were classified as new‐onset cases. Age‐matched controls were individuals who did not have symptoms at either the initial or subsequent surveys. Key Results The overall response rate was 78% to the initial survey and 52% to the follow‐up survey. Based on the responses, 316 participants had a new onset of an FGID (43 IBS constipation, 95 IBS diarrhea, 25 IBS mixed, and 153 other FGID s, including FD ) and 250 did not (controls). Around 76% (241/316) of cases reported a non‐enteric infection vs 66% (166/250) of the controls. The frequency of enteric infections was similar between the two groups. Of the new FGID cases, 83% had a non‐enteric infection that was treated with antibiotic. In a logistic regression model, treatment with antibiotics for a non‐gastrointestinal infection was associated with the development of an FGID (odds ratio = 1.90; 95% CI : 1.21–2.98; p = 0.005), after adjusting for age and sex. Conclusions & Inferences Based on a case–control study, treatment of a non‐gastrointestinal infection with antibiotics appears to be a risk factor for development of an FGID .
Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas
Braggio, Esteban , Wier, Scott Van, Ojha, Juhi, McPhail, Ellen D. , Asmann, Yan W. , Egan, Jan B. , Ayres-Silva, Jackline de Paula , Schiff, David , Lopes, M. Beatriz S. , Decker, Paul A. , Valdez, Riccardo, Tibes, Raoul , Eckloff, Bruce W., Stewart, A. Keith, Van Wier, Scott, McPhail, Ellen, Egan, Jan, Eckloff, Bruce, O'Neill, Brian Patrick, McPhail, Ellen Darcy , Decker, Paul A. , Witzig, Thomas E. , Fonseca, Rafaël , O’Neill, Brian Patrick , Braggio, Esteban

Mayo Clinic

Clinical Cancer Research | May 19, 2015 | Volume: 21 | Issue: 17 | Pages: 3986-3994

10.1158/1078-0432.ccr-14-2116 | PMID 25991819 Get It

Abstract Purpose: Primary central nervous system lymphoma (PCNSL) is an aggressive non-Hodgkin lymphoma confined to the central nervous system. Whether there is a PCNSL-specific genomic signature and, if so, how it differs from systemic diffuse large B-cell lymphoma (DLBCL) is uncertain. Experimental Design: We performed a comprehensive genomic study of tumor samples from 19 immunocompetent PCNSL patients. Testing comprised array-comparative genomic hybridization and whole exome sequencing. Results: Biallelic inactivation of TOX and PRKCD was recurrently found in PCNSL but not in systemic DLBCL, suggesting a specific role in PCNSL pathogenesis. In addition, we found a high prevalence of MYD88 mutations (79%) and CDKN2A biallelic loss (60%). Several genes recurrently affected in PCNSL were common with systemic DLBCL, including loss of TNFAIP3, PRDM1, GNA13, TMEM30A, TBL1XR1, B2M, CD58, activating mutations of CD79B, CARD11, and translocations IgH-BCL6. Overall, B-cell receptor/Toll-like receptor/NF-κB pathways were altered in >90% of PNCSL, highlighting its value for targeted therapeutic approaches. Furthermore, integrated analysis showed enrichment of pathways associated with immune response, proliferation, apoptosis, and lymphocyte differentiation. Conclusions: In summary, genome-wide analysis uncovered novel recurrent alterations, including TOX and PRKCD, helping to differentiate PCNSL from systemic DLBCL and related lymphomas. Clin Cancer Res; 21(17); 3986–94. ©2015 AACR.
Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures
Stone, Jennifer , Thompson, Deborah J. , dos‐Santos‐Silva, Isabel , Lindström, Sara , Hazra, Aditi , Li, Jingmei , Eriksson, Louise , Jensen, Matt , Cunningham, Julie M. , Purrington, Kristen S. , Brown, Judith, Leyland, Jean, Warren, Ruth , Luben, Robert , Smith, Paula , Jud, Sebastian M. , Heusinger, Katharina, Beckmann, Matthias W. , Douglas, Julie A. , Shah, Kaanan P., Chan, Heang‐Ping , Helvie, Mark A. , Kolonel, Laurence N. , Woolcott, Christy , Haiman, Christopher A. , Giles, Graham G. , Baglietto, Laura , Krishnan, Kavitha , Southey, Melissa C. , Apicella, Carmel, Andrulis, Irene L. , Knight, Julia A. , Ursin, Giske , Alnæs, Grethe I.G., Kristensen, Vessela N. , Børresen‐Dale, Anne‐Lise , Bolla, Manjeet K. , Wang, Qin , Michailidou, Kyriaki , Simard, Jacques , Dunning, Alison M. , Easton, Douglas F. , Fasching, Peter A. , Vachon, Celine M. , Durocher, Francine , Cunningham, Julie, Scott, Christopher G. , Tamimi, Rulla M. , Kraft, Peter , Czene, Kamila , Hall, Per N , Olson, Janet E. , Couch, Fergus J. , Khaw, Kay‐Tee , Wareham, Nicholas J. , Marchand, Loı̈c Le , Maskarinec, Gertraud , Gram, Inger Torhild , Dennis, Joe , Pharoah, Paul D.P. , Pankratz, V. Shane , Hopper, John L. , Vachon, Celine M. , Luben, Robert N , Giles, Graham G , Southey, Melissa C , Dunning, Alison M , Li, Jingmei , Michailidou, Kyriaki , Simard, Jacques , Stone, Jennifer , Baglietto, Laura , Purrington, Kristen S , Chan, Heang-Ping

Mayo Clinic

Cancer Research | April 10, 2015 | Volume: 75 | Issue: 12 | Pages: 2457-2467

10.1158/0008-5472.can-14-2012 | PMID 25862352 Get It

Abstract Mammographic density measures adjusted for age and body mass index (BMI) are heritable predictors of breast cancer risk, but few mammographic density-associated genetic variants have been identified. Using data for 10,727 women from two international consortia, we estimated associations between 77 common breast cancer susceptibility variants and absolute dense area, percent dense area and absolute nondense area adjusted for study, age, and BMI using mixed linear modeling. We found strong support for established associations between rs10995190 (in the region of ZNF365), rs2046210 (ESR1), and rs3817198 (LSP1) and adjusted absolute and percent dense areas (all P < 10−5). Of 41 recently discovered breast cancer susceptibility variants, associations were found between rs1432679 (EBF1), rs17817449 (MIR1972-2: FTO), rs12710696 (2p24.1), and rs3757318 (ESR1) and adjusted absolute and percent dense areas, respectively. There were associations between rs6001930 (MKL1) and both adjusted absolute dense and nondense areas, and between rs17356907 (NTN4) and adjusted absolute nondense area. Trends in all but two associations were consistent with those for breast cancer risk. Results suggested that 18% of breast cancer susceptibility variants were associated with at least one mammographic density measure. Genetic variants at multiple loci were associated with both breast cancer risk and the mammographic density measures. Further understanding of the underlying mechanisms at these loci could help identify etiologic pathways implicated in how mammographic density predicts breast cancer risk. Cancer Res; 75(12); 2457–67. ©2015 AACR.
Relationship between sarcopenia, six‐minute walk distance and health‐related quality of life in liver transplant candidates
Yadav, Anitha, Chang, Yu‐Hui, Carpenter, Sarah, Silva, Alvin C. , Rakela, Jorge , Aqel, Bashar , Byrne, Thomas , Douglas, David D., Vargas, Hugo E. , Carey, Elizabeth J. , Aqel, Bashar A. , Vargas, Hugo E

Mayo Clinic

Clinical Transplantation | November 27, 2014 | Volume: 29 | Issue: 2 | Pages: 134-141

10.1111/ctr.12493 | PMID 25430554 Get It

AbstractSarcopenia, or loss of skeletal muscle mass, is associated with increased mortality and morbidity in liver transplant (LT) candidates. Six‐minute walk distance (6MWD) and health‐related quality of life (HRQOL) as assessed by short form 36 scores (SF‐36) also impact clinical outcomes in these patients. This study explored the relationship between the sarcopenia, 6MWD, and HRQOL in LT candidates. Sarcopenia was evaluated based on skeletal muscle mass index (SMI) quantified from abdominal computed tomography. Patients were followed until death, removal from the wait list or the end of the study period. Two hundred and thirteen patients listed for LT were included. The mean SMI, 6MWD and mean gait speed were 54.3 ± 9.7, 370.5 m and 1 m/s, respectively. Sarcopenia was noted in 22.2% of LT candidates. There was no correlation between sarcopenia, 6MWD, and SF‐36 scores. The 6MWD, but not sarcopenia, was an independent predictor of mortality (hazard ratio = 2.1 [0.9–4.7]). In summary, sarcopenia did not emerge as a significant predictor of waitlist mortality and also failed to correlate with either functional capacity or HRQOL in LT candidates. In patients with ESLD awaiting LT, 6MWD appears to be a more useful prognostic indicator than the presence of sarcopenia.
Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia
Ojha, Juhi, Ayres-Silva, Jackline de Paula , Secreto, Charla, Tschumper, Renee C. , Rabe, Kari G. , Dyke, Daniel Van, Braggio, Esteban , Tschumper, Renee, Rabe, Kari, Van Dyke, Daniel, Slager, Susan, Dyke, Daniel L. Van , Slager, Susan L. , Shanafelt, Tait D. , Fonseca, Rafaël , Kay, Neil E. , Chaffee, Kari G. , Braggio, Esteban

Mayo Clinic

Blood | November 6, 2014 | Volume: 125 | Issue: 3 | Pages: 492-498

10.1182/blood-2014-06-580563 | PMID 25377784 Get It

Key Points Deep sequencing identifies a significant reservoir of subclonal mutations affecting key genes in CLL pathogenesis. Convergent evolution of genetic lesions in tumor subclonal populations is recurrently found in CLL.
Clinical, positron emission tomography, and pathological studies of DNAJC13 p.N855S Parkinsonism
Appel‐Cresswell, Silke , Rajput, Ali H. , Thompson, Christina, Silva, Vanessa , McKenzie, Jessamyn , Dinelle, Katherine, McCormick, Siobhan, Vilariño‐Güell, Carles , Stoessl, A. Jon , Dickson, Dennis W. , Robinson, Chris , Farrer, Matthew J. , Rajput, Alex, Sossi, Vesna , Dickson, Dennis W , Appel-Cresswell, Silke

Mayo Clinic

Movement Disorders | September 3, 2014 | Volume: 29 | Issue: 13 | Pages: 1684-1687

10.1002/mds.26019 | PMID 25186792 Get It

AbstractBackgroundFamilies of Dutch‐German‐Russian Mennonite descent with multi‐incident parkinsonism have been identified as harboring a pathogenic DNAJC13 p.N855S mutation and are awaiting clinical and pathophysiological characterization.MethodsFamily members were examined clinically longitudinally, and 5 underwent dopaminergic PET imaging. Four family members came to autopsy.ResultsOf the 16 symptomatic DNAJC13 mutation carriers, 12 had clinically definite, 3 probable, and 1 possible Parkinson's disease (PD). Symptoms included bradykinesia, tremor, rigidity, and postural instability, with a mean onset of 63 years (range, 40‐85) and slow progression. Eight of ten subjects who required treatment had a good levodopa response; motor complications and nonmotor symptoms were observed. Dopaminergic PET imaging revealed rostrocaudal striatal deficits typical for idiopathic PD in established disease and subtle abnormalities in incipient disease. Pathological examinations revealed Lewy body pathology.ConclusionPD associated with a DNAJC13 p.N855S mutation presents as late‐onset, often slowly progressive, usually dopamine‐responsive typical PD. © 2014 International Parkinson and Movement Disorder Society